[Edaily Starin Reporter KIM HYUNSIK ] Creator Nittmol Cash (real name Cha Cheong-il), a former backup dancer, is suspending his activities in the wake of a controversy surrounding his private life. Nitmol Cash (Photo: NOB Entertainment)
His agency, NOB Entertainment, released a statement on the 29th, saying, “We have verified the facts with Nitmol Cash regarding the content posted online about him.” They went on to explain, “During the verification process, we confirmed that Nittmol Cash had engaged in inappropriate words and actions, and we have decided, by mutual agreement, to suspend all of his activities.” Previously, a post by a person identified as “A,” who claimed to be Nittomol Cash’s former partner, appeared online. A alleged that Nittomol Cash had subjected her to verbal and physical abuse during their past relationship. A also claimed that Nittomol Cash had spoken ill of fellow content creators and made derogatory remarks about children with disabilities. The agency stated, “We apologize to those who have been harmed by Nittomol Cash’s actions,” adding, “We are currently verifying the facts, and we will take necessary measures based on the findings.” They added, “We are also consulting with relevant companies regarding currently scheduled advertising and content projects to take the necessary follow-up measures.” Nimol Cash previously performed on stage with BTS during his time as a backup dancer. In 2024, he formed the duo ASMRZ with comedian Kim Kyung-wook and released the dance track “Good Night, Miss.”
“China’s Changxin Memory is catching up at an astonishing pace. Having rapidly dominated the general-purpose semiconductor market, it is now challenging the high-specification semiconductor and high-b…
Pulmuone Corporate’s operating profit for the third quarter of this year fell to one-tenth of the level recorded in the same period last year. Although sales increased, profitability in its domestic b…
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…